23andMe cuts 40% of its workforce and discontinues therapeutics division
Back in September, all of 23andMe’s independent directors also resigned from its board — in a rare move that followed drawn-out negotiations with Wojcicki, who has been trying to take the company private. The seven resigning directors said they had yet ...
Me is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the ...
Embattled genetic testing provider 23andMe said on Tuesday that revenue declined from a year earlier, a day after the company ...
In another blow to the company, seven of 23andMe’s eight-strong board resigned in September. The firm's independent ...
Me has appointed three new independent directors to its board following the mass resignation of all seven of its previous ...
In addition to workforce reductions, 23andMe has also decided to discontinue its therapeutic ... The situation worsened in ...
Back in September, all of 23andMe’s independent directors also resigned from its board — in a rare move that followed ...
In September, independent directors of the Board of 23andMe sent a letter to Anne Wojcicki, Chief Executive Officer, Co ...
On Tuesday, Wojcicki announced the new additions to 23andMe’s board: Andre Fernandez, a former CFO at WeWork, Inc., and NCR ...
Shares were hovering below $1 until 23andMe announced a 1-for-20 reverse stock split in October. In September, all seven of ...
Holding “announced a business restructuring to streamline operations and reduce costs. In addition, 23andMe is discontinuing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback